Carmustine
- Generic Name
- Carmustine
- Brand Names
- Bicnu, Gliadel, Carmustine medac (previously Carmustine Obvius)
- Drug Type
- Small Molecule
- Chemical Formula
- C5H9Cl2N3O2
- CAS Number
- 154-93-8
- Unique Ingredient Identifier
- U68WG3173Y
- Background
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index,...
- Indication
For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.
- Associated Conditions
- Astrocytoma, Brain Stem Gliomas, Ependymoma, High Grade Glioma: Glioblastoma (GBM), Medulloblastomas, Metastatic Brain Tumors, Mycosis Fungoides (MF), Newly Diagnosed High-Grade Glioma, Recurrent Glioblastoma Multiforme (GBM), Refractory Hodgkin Lymphoma, Refractory Multiple Myeloma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- -
Dacarbazine and Carmustine in Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2018-04-04
- Lead Sponsor
- Western Regional Medical Center
- Target Recruit Count
- 1
- Registration Number
- NCT01692691
- Locations
- 🇺🇸
Western Regional Medical Center, Goodyear, Arizona, United States
Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma
- First Posted Date
- 2012-08-03
- Last Posted Date
- 2012-08-03
- Lead Sponsor
- Shandong Lanjin Pharmaceuticals Co.,Ltd
- Target Recruit Count
- 236
- Registration Number
- NCT01656980
- Locations
- 🇨🇳
Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, Beijing, China
Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2012-07-31
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 10
- Registration Number
- NCT01653418
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2012-02-24
- Last Posted Date
- 2014-09-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT01538472
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2012-01-18
- Last Posted Date
- 2021-08-17
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 113
- Registration Number
- NCT01511562
- Locations
- 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
- Conditions
- Interventions
- First Posted Date
- 2011-12-28
- Last Posted Date
- 2013-11-25
- Lead Sponsor
- Texas Oncology Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT01500161
- Locations
- 🇺🇸
Texas Oncology, Amarillo, Texas, United States
Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2011-11-22
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT01476839
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT
- First Posted Date
- 2010-10-13
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 3
- Registration Number
- NCT01220297
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)
- Conditions
- Interventions
- First Posted Date
- 2010-08-23
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Duke University
- Target Recruit Count
- 41
- Registration Number
- NCT01186406
- Locations
- 🇺🇸
The Preston Robert Tisch Brain Tumor Center, Durham, North Carolina, United States
Autologous Transplant in HIV Patients (BMT CTN 0803)
- Conditions
- Interventions
- First Posted Date
- 2010-06-10
- Last Posted Date
- 2023-01-04
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 43
- Registration Number
- NCT01141712
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸University of CA, SF, San Francisco, California, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.